Response Guided Interferon Therapy for Genotype 3 of Chronic Hepatitis C: Compliance and Outcome

Shahid Sarwar¹, Anwaar A. Khan², Shandana Tarique³

ABSTRACT

Objective: To determine compliance and improvement in sustained viral response (SVR) by following response guided therapy (RGT) plan of interferon and ribavirin, for genotype 3 in chronic hepatitis C.

Methods: Patients with chronic hepatitis C genotype 3, who were eligible for interferon-ribavirin therapy and consented for RGT, were included. Those with no rapid viral response (RVR), having coarse echotexture of liver or undergoing re-treatment, were advised 48 week treatment whereas, rest had 24 week standard therapy. PCR for HCV RNA checked 6 months after discontinuing treatment, was the primary end point of study.

Results: Of 154 patients, included in the study with mean age of 39.9 (±10.84) and male to female ratio 1.4/1 (94/60), majority of patients, 136 (88.4%) were treatment naïve whereas, 18 (11.6%) were being retreated. On ultrasound, 63 (40.9%) patients had coarse liver and 33 (21.4%) had splenomegaly. RVR was achieved in 99 (64.3%) patients. Overall 66 (42.8%) patients merited extended duration of therapy as per RGT plan but only 22 (33%) were compliant. Treatment related side effects were the dominant reason for declining RGT in 33 (75%) patients. SVR was noted in 111 (72.1%) patients. Those patients with extended therapy (RGT), had SVR 90.9% (20/22), although, better but statistically not significant than those who stopped therapy at 6 months 77.2% (34/44) (p value 0.11).

Conclusion: Response guided therapy plan did not improve SVR to pegylated interferon and ribavirin therapy in patients with genotype 3 and it has low patient compliance due to treatment related side effects.

KEY WORDS: Chronic hepatitis C, Compliance, Genotype 3, Response guided therapy, Sustained viral response (SVR).

How to cite this: Sarwar S, Khan AA, Tarique S. Response Guided Interferon Therapy for Genotype 3 of Chronic Hepatitis C: Compliance and Outcome. Pak J Med Sci 2015;31(4):843-847. doi: http://dx.doi.org/10.12669/pjms.314.7293

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Hepatitis C continues to be a challenge for human race due to its increasing prevalence and its potentially lethal long term complications.¹Ever since identification of this virus, efforts to find effective treatment are underway and a lot has been achieved i.e., combination therapy, pegylated interferon with ribavirin to directly acting antiviral (DAA) agents, introduced only recently.² Due to prohibitive cost of DAA agents, interferon is likely to continue as predominant form of treatment available to patients with hepatitis C particularly in the developing countries like Pakistan.³⁴ Despite having genotype 3 as dominant variety in our population, viral clearance as determined by sustained viral response (SVR) is
around 65-70%, less than what is reported from other regions of the world with this genotype.\(^5\) Moreover, standard interferon therapy which is no more standard of care as per international guidelines and achieves even lesser viral clearance as compared to pegylated interferon, is still the dominant form of treatment available to our patients.\(^6\)

In order to enhance results of combination therapy, response guided therapy (RGT) is recommended by all major societies of liver diseases.\(^7\) RGT is aimed at improving viral clearance by prolonging treatment in patients with slower response to interferon therapy during initial part of therapy. Number of studies have shown promising results with response guided treatment plan with improvement in SVR,\(^8,9\) although, it adds to cost of treatment in form of additional investigations and more medications.

This study addresses the impact of RGT in our population as we still are unaware of true merits of this regime in our patients with chronic hepatitis C. Moreover, it highlights the issue of compliance of injection therapy in our patients due to side effects associated with use of interferon.\(^10\) Objectives of our study, therefore, were to determine patient acceptance and impact on outcome in terms of sustained viral response of RGT, in genotype 3 patients in our population.

**METHODS**

Patients included in the study were those coming to Hepatology Clinic at the DHMC, Lahore from November 2011 to March 2014. Only confirmed cases of chronic hepatitis C as determined by positive polymerase chain reaction (PCR) test for HCV RNA, with lower limit of detection as 10 IU/ml and genotype 3, were included. Patients with evidence of decompensated liver disease i.e. presence of ascites on ultrasound examination, history of hepatic encephalopathy or gastrointestinal bleeding due to esophagealvarices were excluded. Patients with platelet count less than 80,000/mm\(^3\), International normalization ratio (INR)> 1.5, serum albumin < 3.2 gm/dl, serum creatinine> 1.5 mg/dl or deranged thyroid profile were not included. Presence of co-morbid illnesses i.e. uncontrolled hypertension, diabetes mellitus, unstable cardiac failure, stroke, major depression were excluded.

Choice of interferon to be used (standard vs pegylated) was made after consultation with patients in view of their economic status. Patients were explained response guided therapy plan as suggested in guidelines of Asia Pacific Association for Study of Liver Diseases (APASL).\(^11\) Informed consent was obtained on start of study.

Patients were treated with pegylated interferon alpha 2a, 180µg subcutaneously on weekly basis with oral ribavirin 15 mg/kg/day. Those opting for standard interferon, received 3 million units thrice a week along with above dose of ribavirin. All patients were followed-up initially at fortnight, and then monthly till completion of treatment, thereafter, 3 monthly for 6 months to determine SVR. Complete blood count and liver function tests were checked on each follow up visit, along with evaluation and management of treatment related side effects. Patients had their quantitative HCV RNA status checked by real time PCR after one month of treatment to determine rapid viral response (RVR). If RVR was achieved, patients were advised to complete 6 month treatment. In case of positive PCR at one month, real time quantitative PCR for HCV RNA was repeated after 12 injections. Patients with negative PCR at 12 weeks (Complete Early viral response cEVR) or positive PCR but more than two log decline of viral load as compared with baseline viral load (Partial EVR), were advised to continue treatment for one year while those with less than 2 log decline in viral load after 3 months therapy were advised to discontinue therapy.

Patients not willing to continue therapy after six months despite indication were again counseled regarding need for extended therapy. Once treatment completed, HCV RNA was determined by PCR to document end of treatment response (ETR). Patients with positive PCR were non-responders whereas, those with negative PCR at end of treatment were checked again after 6 month to document sustained viral response (SVR) or relapse.

**Statistical analysis:** Data were analyzed using SPSS 20. Numerical variables were described as mean ± standard deviation or median value. Categorical variables were given as percentage. Patients who opted for extended treatment and those declining treatment extension, were compared using unpaired two tailed student’s t test for numerical variables and chi square \(\chi^2\) for nominal and categorical variables.

**RESULTS**

Of the 154 patients included in the study, mean age was 39.9 (±10.84) whereas, male to female ratio was 1.4/1 (94/60). Genotype was 3a in 152 (98.7%) and 3b in two patients. Majority of patients, 136
(88.4%) were treatment naïve, whereas, 18 (11.6%) were non-responders to standard interferon therapy in past. On ultrasound examination 63 (40.9%) patients had coarse texture liver and 33 (21.4%) had splenomegaly.

Pegylated interferon along with ribavirin was started in 106 (68.8%) patients whereas, 48 (31.2%) opted for standard interferon and ribavirin. All patients had their HCV RNA checked by PCR at one month interval, after starting treatment, to determine rapid viral response (RVR). HCV RNA was undetectable at one month in 99 (64.3%) of patients whereas, 55 (35.7%) failed to achieve RVR. Among 55 patients with no RVR, only 18 (32.7%) had extension of treatment duration. Only 2 (11.1%) of 18 treatment experienced patients, had continued treatment beyond 6 months. Of 63 patients with coarse liver on ultrasound, 50 (72.4%) were eligible for extended therapy but only 13 (26%) were treated beyond 6 months with combination therapy. Overall 66 (42.8%) patients merited extended duration of therapy as per RGT plan but only 22 (33%) received RGT. Of 44 patients whose therapy was not extended despite indications, 33 (75%) declined RGT due to side effects of treatment and 11 (25%) due to non-affordability. We compared patients with and without SVR as shown in Table-I.

Impact of treatment extension on SVR, due to different indications is shown in Table-II. Of those patients, who met indications for extended treatment, SVR with response guided therapy was 90.9% (20/22), better, but statistically not significantly superior, than SVR in patients who stopped therapy at 6 months despite indication 77.2% (34/44) (p value 0.11).

Table-I: Comparison of patient with SVR and those with no SVR.

| Variables                        | Patients with SVR (n=111) | No SVR (n=43) | P value |
|----------------------------------|---------------------------|---------------|---------|
| Mean Age(years)                  | 38.59 (10.6)              | 43.47 (10.7)  | 0.012   |
| Mean Baseline                    | 93.76 (78.3)              | 100.4 (60.4)  | 0.61    |
| Mean Serum albumin g/dl          | 4.1 (0.39)                | 4.04 (0.47)   | 0.32    |
| Platelet (x 109/L)               | 190.4 (64.4)              | 199.3 (93.2)  | 0.5     |
| No of Patients                   | 41                        | 22            | 0.25    |
| with Coarse liver texture        |                           |               |         |
| with Spleenomegaly               |                           |               |         |
| No of Patients                   | 81                        | 18            | <0.001  |

Table-II: SVR in patients with indication for extended therapy as per Response guided therapy.

| Indication for extension | Treatment extended SVR (%) | Treatment not extended SVR (%) | P value |
|-------------------------|----------------------------|-------------------------------|---------|
| Coarse texture liver    | 92.3                       | 78.3                          | 0.26    |
| No RVR                  | 89.4                       | 81.5                          | 0.78    |
| RVR but coarse liver    | 100                        | 74.07                         | 0.11    |
| All patients            | 90.2                       | 77.2                          | 0.11    |

DISCUSSION

Genotype 3 is the most underrated and poorly understood type of hepatitis C virus. For years,
we regarded it as good genotype with favorable outcome of interferon therapy. But majority of studies from Asian region have shown lower SVR as compared with western data. Batool et al.\(^7\) noted 68% response rate in genotype 3 whereas, it was around 72% in a study of 721 patients from Lahore.\(^8\) Niederau C et al. concluded that patients with genotype 3 have more fibrosis of liver and only 56.9% of them respond to interferon therapy.\(^9\) SVR of 72.1% in our study patients corroborates with the other reported studies.\(^10\) It is disturbing to see that new emerging directly acting drugs (DAAs) with promise of interferon free treatment of hepatitis C are reported to be less effective in genotype 3.\(^11\)

Impact of genotype 3 on insulin resistance and lipid metabolism is presumed to be one factor responsible for its poor response to treatment.\(^12\)

In order to address this issue of inadequate response, response guided therapy was introduced. Rapidity of viral disappearance RVR, is directly related to viral clearance,\(^13\) also seen in this study. SVR in patients with RGT was above 90%, better than response in patients who refused extended therapy despite indications (77%), but the difference was not statistically significant. It is most likely due to small number of patients on RGT plan. Fried MW et al. noted that patients with RVR have better SVR ranging from 88-100% across all genotypes,\(^14\) but SVR in patients without RVR is low, 45% reported by Shiffman ML,\(^15\) and 56% in Dalgard O study,\(^16\) with 24 week treatment. It is due to less than adequate response in patients failing to achieve RVR, that both EASL\(^7\) and APASL\(^11\) guidelines recommend, extension of treatment duration to 48 weeks in genotype 3. Although, our study fails to show this benefit of RGT, SVR in patients with RGT was better, (> 90%) than in patients with RVR treated for 24 weeks (81.8%). If number of patients on RGT is higher, it may become statistically significant, as the trend shows. Ruddy KR stresses the importance of identifying indicators of poor response in addition to no RVR i.e. African origin, cirrhosis, unfavorable IL28B and decreased interferon sensitivity to maximize benefits of RGT.\(^17\)

Our study brings forth the issue of compliance and acceptability of RGT, among patients. Only 33% of patients, needing extended therapy, continued treatment beyond 6 months. Despite, agreeing with RGT plan at start of treatment, majority of patients refused treatment extension due to treatment related side effects. In as much as, adverse events tend to increase over time, 48 week treatment becomes difficult to tolerate as compared with 24 week therapy.\(^18\) Side effects i.e. fatigue, weight loss, myalgia and depression do affect quality of life adversely, thus, limiting therapy from extending to 48 weeks.\(^19\)

Response guided interferon therapy can marginally improve the response rate to interferon therapy as seen in our study, but due to poor compliance of extended therapy, number of patient on RGT were limited, it merits a larger case control study to see better results. Due to prohibitively high price of DAAs, these will not be affordable for majority of our population; it is therefore, prudent to further explore RGT and such other measure to treat patients with Hepatitis C in Pakistan.

**CONCLUSION**

Response guided therapy plan does not improve response to peg interferon and ribavirin combination therapy in patients with HCV genotype 3 and it has suboptimal patient compliance due to treatment related side effects.

**Declaration of interest:** None

**Funding:** None

**REFERENCES**

1. Karahasanoglu FB1, Asan A, Sacar S, Turgut H. Costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections. Balkan Med J. 2013;30(4):375-381.
2. Kim do Y, Ahn SH, Han KH. Emerging therapies for hepatitis C. Gut Liver. 2014;8(5):471-479.
3. Heidrich B, Wiegand SB, Buggisch P, Hinrichsen H, Link R, Moller B, et al. Treatment of Naive Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. PLoS One. 2014;9(10): e108751.
4. Parekh PJ, Shiffman ML. The role of interferon in the new era of hepatitis C treatments. Expert RevGastroenterolHepatol. 2014;8(6):649-656.
5. Khan AA, Sarwar S. Response to combination therapy in hepatitis virus C genotype 2 and 3 J Coll Physicians Surg Pak. 2009;19(8):473-477.
6. Sarwar S, Khan AA, Tarique S. Pegylated vs. standard interferon in combination with ribavirin for genotype 2 and 3 in chronic hepatitis C - 10 years experience in local population. Ann King Edward Med Uni. 2011;17(2):108-112.
7. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. European Association for the Study of the Liver. J Hepatol. 2011;55(2):245-264.
8. Ferenci P. Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow. Best PractRes ClinGastroenterol. 2012;26(4):463-469.
9. Gellad ZF, Muir AJ, McHutchison JG, Sievert W, Sharara AI, Brown KA, et al. Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. Value Health. 2012;15(6):876-886.
Response guided therapy in Hepatitis C: compliance and outcome

10. Sundus A, Siddique O, Abbasi Z, Ibrahim MF, Aziz S. Hepatitis patients lost to follow-up at a liver centre in a tertiary care hospital of Karachi, Pakistan - a cross-sectional descriptive study. J Pak Med Assoc. 2013;63(12):1566-1570.

11. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafari W, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. HepatolInt. 2012;6:409-435.

12. Batool U, Qureshi S. Declining sustained viral response in hepatitis C. J Coll Physicians Surg Pak. 2006;16(3):187-191.

13. Niederau C, Mauss S, Schober A, Stoehr A, Zimmermann T, Waizmann M, et al. Predictive factors for sustained viral response after treatment with pegylated interferon alpha 2a and ribavirin in patients infected with hepatitis C genotype 2 and 3. PLoS One 2014; 9(9): 0107592

14. Tapper EB, Afdhal NH. Is 3 the new 1?: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepatol. 2013;20(10):669-677.

15. Jaroszewicz J, Flisiak R, Dusheiko G. A pill for HCV- myth or foreseeable future. Liver Int. 2014;34(1):6-11.

16. Ampuero J, Romero-Gomez M, Reddy KR. Review article: HCV genotype 3-the new treatment challenge. Aliment PharmacolTher. 2014;39(7):686-698.

17. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid viral response is the most important predictor of sustained viral response across genotypes in patients with chronic hepatitis C viral infection. J Hepatol. 2011;55(1):69-75.

18. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferononalpha 2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357:124-134.

19. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004;40:1260-1265.

20. Ruddy KR, Lin F, Zoulin F. Response guided and unguided treatment of chronic hepatitis C. LivInt. 2012;32(1):64-73.

21. Hadziyannis SJ, Sette H, Jr Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha 2a and ribavirin combination in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.

22. Nogueira JB, Sena LC, QuintansJde S, Almeida JR, Franca AV, Junior LJ. Side effects of the therapy with peginterferon and ribavirin in chronic hepatitis C: a small audit. J Pharm Pract. 2012;25(1):85-88.

Author’s Contributions:

Shahid Sarwar: Designed the study and did data collection, analysis, interpretation and drafting of article followed by final approval.

Anwaar. A. Khan: Conceived the study, revised the draft critically and did final approval of article.

Shandana Tarique: Data collection, revision of draft critically and final approval of article.

Shahid Sarwar takes the responsibility and is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.